Oral semaglutide dose: what the tablet schedule actually looks like

The misconception: higher dose straight away means better results, faster

One of the most common things people assume when starting any weight-loss medicine is that the highest dose is the target, and the lower starting doses are just a warm-up to get through quickly. With the oral semaglutide dose schedule, that thinking can work against you.

Semaglutide slows gastric emptying and acts on appetite-regulating pathways in the brain. Starting at the top of the schedule would flood those systems before the body has adapted, and the result is typically a sharp increase in nausea, vomiting and digestive discomfort. The graduated schedule (1.5 mg for the first month, then 4 mg, then 9 mg, then 25 mg) is built specifically to reduce that early burden. Evidence from the OASIS 4 phase 3 trial found that gastrointestinal side effects, while common (present in around 74% of participants on oral semaglutide), were generally mild to moderate and tended to ease as the body adjusted. Rushing through the steps does not give that adjustment time to happen.

The practical upshot: if your prescriber keeps you at a lower dose for longer than you expected, that is clinical judgement, not an oversight. The dose that produces the most sustained benefit is the one your system can tolerate consistently, not the one reached soonest. Questions about your personal pace of titration belong in a conversation with your prescriber, not in a general article, but if you want to understand how semaglutide oral dosage for weight loss is structured and why each step exists, that detail makes it much easier to follow the schedule with confidence.

How the four dose steps work in practice

The Wegovy tablet dose ladder has four rungs, each requiring at least one month before moving up. The starting tablet is 1.5 mg. After a minimum of four weeks, a prescriber may move you to 4 mg; then to 9 mg; then to 25 mg as the maintenance dose. That means the earliest anyone reaches the full maintenance dose is around four months in, though many people take longer, and that is normal.

How the tablet works at the absorption level is worth knowing, because it shapes the taking instructions. Oral semaglutide is co-formulated with an absorption enhancer called SNAC, which allows the drug to cross the stomach wall. That process only functions reliably on a genuinely empty stomach with very little liquid. The instruction (first thing in the morning, plain water only (no more than around 120 ml), at least 30 minutes before anything else) is not arbitrary. Take it with coffee, or after breakfast, and absorption can fall significantly. One of the questions our prescribers hear regularly is why results seem inconsistent; inconsistent timing is often part of the answer.

For people already established on the 2.4 mg weekly semaglutide injection who are switching to the tablet form, clinical guidance allows moving directly to the 25 mg tablet rather than restarting the full escalation, subject to prescriber assessment. If you are considering that switch, the Wegovy oral dose overview covers the transition in more detail.

What the trial evidence says about the 25 mg maintenance dose

The OASIS 4 trial (307 adults with obesity or overweight plus at least one weight-related condition, without type 2 diabetes, followed for 64 weeks) is the primary evidence base for the oral semaglutide dose for weight loss. Participants on 25 mg oral semaglutide achieved an average weight reduction of around 13.6% compared with around 2.4% on placebo, regardless of adherence levels. Among those who stayed fully consistent with the regimen across the trial period, average loss was closer to 17%. That distinction matters: the 17% figure reflects optimal adherence, not typical use.

For context on how these figures compare with the injectable form, this breakdown of semaglutide tablet strengths sets out the relationship between dose level and expected effect. The injectable Wegovy 2.4 mg weekly showed around 15% average loss in the STEP 1 trial at 68 weeks; the new 7.2 mg injectable maintenance dose has produced around 20.7% in trials. The tablet sits between those figures in the current evidence, a meaningful result for a once-daily oral medicine with no refrigeration requirement. These figures come from controlled trial conditions alongside lifestyle changes; real-world outcomes vary, and a prescriber will discuss what is realistic for your situation.

The MHRA approval is detailed in the NHS patient information on semaglutide, which covers what the medicine does, common side effects and storage guidance in plain language.

Practical things to know before starting, storage, timing and what changes at each step

No refrigeration is one of the more immediately practical differences between the Wegovy tablet and the injectable pens. The tablets store at room temperature, which makes them straightforward to keep at a desk, in a bag or packed for a trip away. If you are going on holiday or have a period of disrupted routine (the kind of week where meals shift around and mornings get compressed) the 30-minute empty-stomach window becomes the thing to protect. Building the tablet into a fixed morning anchor (before the kettle, before anything else) tends to work better than trying to fit it around a variable schedule.

What changes across the four dose steps is primarily tolerability rather than the taking instructions, which stay the same throughout. Some people notice digestive symptoms more acutely at the 4 mg and 9 mg steps than at the start; others find the transition to 25 mg the most noticeable. Staying well hydrated and eating smaller, lower-fat meals tends to ease GI effects at any stage. If side effects feel unmanageable, that is a conversation for your prescriber, doses can sometimes be held at a level for longer rather than increased on schedule.

Wegovy tablets are not yet available on the NHS; a NICE appraisal would be required before NHS commissioning. At the moment, access is through a private prescription following clinical assessment. If you want to explore whether the oral route suits your situation, the cost overview for Wegovy tablets explains what a private prescription includes. For a broader look at weight-loss treatment options, the treatment overview covers both injectable and oral approaches side by side. When you are ready to speak with a prescriber, start a free consultation with our clinical team, a GPhC-registered Independent Prescriber reviews every application the same day.